Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for ≥ 24 Weeks in People With CF and ≥ 1 F508del Allele: Interim Results of an Open-Label Phase Three Clinical Trial - Griese, M; Costa, S; Linnemann, R W (Am J Respir Crit Care Med, 2020)
et al.